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Summary
Loss of pigment epithelium-derived factor (PEDF, SERPINF1) in cancer cells is associated with 
poor prognosis and metastasis, but the contribution of stromal PEDF to cancer evolution is poorly 
understood. Therefore, we investigated the role of fibroblast-derived PEDF in melanoma 
progression. We demonstrate that normal dermal fibroblasts expressing high PEDF levels 
attenuated melanoma growth and angiogenesis in vivo, whereas PEDF-depleted fibroblasts exerted 
tumor-promoting effects. Accordingly, mice with global PEDF knockout were more susceptible to 
melanoma metastasis. We also demonstrate that normal fibroblasts in close contact with PEDF-
null melanoma cells lost PEDF expression and tumor suppressive properties. Further mechanistic 
investigations underlying the crosstalk between tumor and stromal cells revealed that melanoma 
cells produced PDGF-BB and TGF-β, which blocked PEDF production in fibroblasts. Notably, 
cancer-associated fibroblasts (CAF) isolated from patient-derived tumors expressed markedly low 
levels of PEDF. Treatment of patient CAF and TGF-β-treated normal fibroblasts with exogenous 
PEDF decreased the expression of CAF markers and restored PEDF expression. Finally, 
expression profiling of PEDF-depleted fibroblasts revealed induction of interleukin-8, SERPINB2, 
hyaluronan synthase-2, and other genes associated with tumor promotion and metastasis. 
Collectively, our results demonstrate that PEDF maintains tumor-suppressive functions in 
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fibroblasts to prevent CAF conversion, and illustrate the mechanisms by which melanoma cells 
silence stromal PEDF to promote malignancy.
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Introduction
Past studies demonstrate that non-neoplastic cells in the tumor microenvironment (TME) are 
critical in cancer progression (1). These non-malignant cells include fibroblasts, endothelial 
cells, immune cells and bone marrow-derived myeloid and endothelial progenitors (2). Over 
time, cancer cells engage in crosstalk with the TME and cause non-neoplastic cells to 
assume cancer-associated phenotype supportive of tumor growth and dissemination (3).
Cancer-associated-fibroblasts (CAFs) are the most abundant constituents of the TME (2) and 
atypical fibrotic response in cancers is associated with increased aggressiveness and poor 
prognosis (4). CAFs largely consist of resident fibroblasts; however they also originate from 
bone marrow-derived mesenchymal cells, by epithelial-to-mesenchymal transition (EMT) of 
the resident epithelial and tumor cells (5) and through endothelial-to-mesenchymal transition 
(EndMT) (6). CAFs support tumor progression by supplying growth factors (e.g. basic 
fibroblast growth factor (bFGF), epithelial growth factor and hepatocyte growth factor 
(HGF) and matrix remodeling enzymes, such as matrix metalloproteinases (MMPs) (1). 
CAFs also supply angiogenic growth factors vascular endothelial growth factor (VEGF), 
interleukin (IL)-8 and stromal derived factor (SDF)-1, and facilitate VEGF release from the 
extracellular matrix (ECM) by proteolysis (2, 4). Importantly, CAFs support tumor 
progression by producing ECM components collagens, fibronectin (FN), hyaluronan, 
versican and osteopontin (2). Together, CAFs generate ECM, the growth factors and MMPs, 
which enable and accelerate EMT of the cancer cells and support invasion and metastasis 
(7).
The conversion of fibroblasts to the tumor-associated phenotype is driven by environmental 
stress (hypoxia, reactive oxygen species) (8) and cell-cell communications via secreted 
factors and extracellular vesicles (9). The main cytokines drivers of CAF conversion are 
transforming growth factor beta (TGF-β) (10) and platelet-derived growth factor-BB (PDGF-
BB) (11); together, they are essential for the formation of reactive tumor stroma. Increased 
PDGF-BB expression is observed in most cancers (colon, brain, breast, prostate and lung 
cancers) (12), and high stromal expression of PDGF receptor-beta (PDGFR-β) predicts rapid 
cancer progression and poor prognosis (13). PDGF-BB is critical for fibroblast proliferation 
and recruitment. In contrast, TGF-β mainly drives the conversion of fibroblasts, endothelial 
and mesenchymal stem cells to CAFs (14). A less EndMT is caused by TGF-β and HGF 
(15).
In melanoma, fibroblasts have been identified as a potential cause of therapy resistance; they 
produce growth factors (e.g. nerve growth factor 1), which reactivate Erk1/2 in tumor cells 
(16) or provide ECM, which supports focal adhesions and survival signaling (17). We 
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discovered the loss of pigment epithelial-derived factor (PEDF) as a critical step in 
melanoma transition to the aggressive, metastatic phenotype (18). PEDF is a secreted 
glycoprotein with anti-angiogenic and direct tumor suppressive properties, whose down-
regulation or loss in cancer enables hyperproliferation, migration and invasion (19). PEDF 
also impedes tumor angiogenesis by restricting migration (20) and causing apoptosis 
induction in proliferating endothelial cells (21), via peroxisome proliferation-activated 
receptor-γ (PPAR-γ) and p53 pathways (22, 23) and through extrinsic death signaling by 
CD95L and TRAIL (21, 24, 25). Recent data suggest that PEDF mitigates tumor-promoting 
inflammation through conversion of macrophages towards tumor-reactive M1 phenotype 
(26, 27). Importantly, we have demonstrated that PEDF is produced at high levels by normal 
melanocytes but is lost in aggressive, metastatic melanoma (18) and this loss alters Rho/Rac 
signaling causing amoeboid invasion, extravasation and metastasis (28).
To date, most studies were focused on the mechanisms and consequences of PEDF loss in 
the neoplastic cells. One study describes the tumor-promoting effect of global PEDF loss 
(29), however, the mechanisms that hinder PEDF expression in the tumor stroma and the 
specific consequences of this loss are unknown.
Here, we investigate the role of fibroblast-derived PEDF in melanoma progression using an 
in vivo model that employs PEDF-null primary dermal fibroblasts generated by shRNA 
knockdown. To elucidate the effects of fibroblast-derived PEDF on melanoma progression, 
we compared tumor growth in mice inoculated with PEDF-negative, highly aggressive 
melanoma cells C8161, alone or with normal PEDF-positive or PEDF-null fibroblasts. We 
discovered that fibroblasts-derived PEDF attenuates the growth and angiogenesis of highly 
aggressive, metastatic melanoma, and that PEDF-null fibroblasts promote melanoma growth, 
proliferation and angiogenesis. In agreement, mice with global knockout of SERPINF1 
(PEDF) gene had higher incidence of spontaneous melanoma metastasis and enhanced lung 
colonization in syngeneic melanoma models.
On the other hand, we demonstrate that close proximity of the normal fibroblasts to 
melanoma cells diminished their tumor suppressive properties in vivo. We also show that 
PEDF expression was attenuated in fibroblasts subjected to hypoxic stress or exposed to the 
secretory milieu in the media conditioned by melanoma cells. Among growth factors 
secreted by the melanoma cells we identified PDGF-BB and TGF-β as critical for the 
suppression of PEDF production in fibroblasts. Importantly, TGF-β had no direct effect of 
PEDF expression but augmented PEDF repression by PDGF-BB by up-regulating PDGFR 
receptor β. We have also found that JNK1/2 and p38 were critical for PEDF repression by 
PEDFG-BB, while PDGFR-β regulation by TGF-β occurred through PI3K, JNK1/2, p38 and 
Erk1/2.
Importantly, we show that PEDF repealed CAF conversion by TGF-β, where it inhibited 
SMAD signaling and attenuated CAF markers, smooth muscle actin (SMA) or vimentin in 
patient-derived CAFs. Finally, PEDF knockdown in fibroblasts caused increased expression 
of multiple genes associated with tumor promotion and metastasis including IL-8, 
SERPINB2 and hylauronan synthase. Together, our results demonstrate the importance of 
fibroblast-derived PEDF in controlling tumor progression and identify crosstalk between 
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tumor cells and fibroblasts, which overcomes the tumor-suppressive effects of stromal 
PEDF.
Materials and Methods
Experimental Animals—Mice were maintained at Northwestern University Center for 
Comparative Medicine according to the National Institutes of Health guidelines and 
following protocols approved by Northwestern University Animal Use & Care Committee. 
HsdNu/Nu nude mice ere from Harlan (Indianapolis, IN); C57BL6 mice were from Jackson 
Laboratories; C57Bl6 SERPINF1−/− mice (Regeneron, Tarrytown, NY) were bred at 
Northwestern University. PEDF silencing was ascertained by RT-PCR/ LacZ expression 
(Supplementary Fig. 1).
Cells—Human melanoma cell line C8161-HA from Dr. Hendrix (Children's Memorial 
Hospital, Chicago, IL) was cultured in RPMI1640 (GIBCO, Grand Island, NY) with 10% 
FBS (HyClone, Waltham, MA), penicillin and streptomycin (P/S, GIBCO). The human 
(A375) and murine (B16F10) melanoma cell lines (American Type Culture Collection, 
Manassas, VA) were maintained in DMEM (GIBCO) with 10% FBS and P/S. Human 
neonatal dermal fibroblasts (HDFs, Northwestern University Skin Disease Research Center, 
SDRC) were cultured in DMEM with 10%FBS and P/S and used between passages 3–10. 
Pooled fibroblasts from multiple donors were used to reduce sample variations. Cells were 
grown at 37°C, 5% CO2. Primary CAFs (see below) were cultured in DMEM with 10% FBS 
and P/S.
Authentication—Human melanoma cell lines were were authenticated by Biosynthesis, 
Inc. (Lewisville, TX) using STR DNA profiling methods. The initial vials were expanded 
and cryopreserved the lab and used no longer than five consecutive passages. Authentication 
certificate is provided (see Supplementary Materials).
Gene silencing—We have used pGIPz lentiviral vectors (Open Biosystems, Huntsville, 
AL) encoding shRNA-mir VL2HS_221662 (sh-PEDF) or scrambled, non-silencing control 
(sh-Scr). Lentiviruses were produced at Northwestern University SDRC Viral Core. 
Silencing was verified by quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) and Western blot.
Subcutaneous tumor inoculation
(a) Co-injection—C8161-HA cells (106) mixed with 4.0×106 Sh-Scr Sh-PEDF HDFs in 
PBS or 100μl vehicle were injected subcutaneously (s.c.) in the flanks of nude mice.
(b) Inoculation at remote sites—C8161-HA cells were injected s.c. into the flanks of 
nude mice, (106/ 100μl/ mouse). When palpable tumors formed, the mice were randomized 
into groups (n=5) and injected in the dorsal midline with Sh-PEDF or Sh-Scr fibroblasts 
(106/ 100μl/ mouse) or 100μl PBS. Tumors were measured twice weekly.
Angiogenesis Assessment—Five-μm sections of paraffin-embedded tissue 
(Northwestern University Mouse Phenotyping Core) were incubated overnight at 4°C with 
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anti-CD31 antibody (BD Pharmingen, Billerica, MA); 2 h at RT with Rhodamine-
conjugated 2° antibodies (Jackson ImmunoResearch) and counterstained with DAPI. Digital 
images of 10 random fields/ group were taken with 20X objective and CD31-positive 
structures quantified (Nikon Elements software, Nikon, Melville, NY).
Proliferation analysis, macrophage infiltration and apoptosis were assessed on paraffin-
embedded sections stained at Northwestern University Mouse Phenotypic Core for Ki67, 
F4/80 o subjected to TUNEL assay. Digital images were taken with 20X objective and 10 
random fields/ group assessed as above.
Metastasis Assays
(a) Spontaneous metastasis—B16F10 cells harvested at 80–90% confluence were 
injected s.c in hindquarters of wild type (WT) SEPINF1KO mice (104/ 100μl/ mouse, n=8). 
After 4 weeks, the mice were euthanized, metastases measured with micro-calipers and 
counted.
(b) Lung colonization—B16F10 cells were injected via 27-gauge needle in the tail veins 
of WT and SEPINF1 KO mice (105/ 100 μl/ mouse, n=5). The animals were sacrificed after 
14 days and the lungs photographed.
(c) Extravasation Assay—Lung extravasation was assessed as described (28). B16F10 
cells were labeled with fluorescent dye CSFE (Life technologies, Grand Island, NY), re-
suspended in PBS (106/ 100μl) and injected into the tail veins of mice (100μl/ mouse, n=3). 
The mice were sacrificed 2 and 24 h post-injection, and fluorescent colonies visualized using 
Nikon AZ-100 microscope (Nikon, Melville, NY, 5X objective) in > 5 random fields.
Conditioned media (CM) preparation—Cells were grown to 70–80% confluence, 
rinsed twice in PBS and placed in serum-free media for 48 h. CM was cleared by 
centrifugation (1500g × 5 min, 4°C), the supernatants concentrated by spin-filtration (3-kDa 
MWCO, Millipore, Billerica, MA) and stored at −80°C. Protein concentration was measured 
using Bradford Assay (Thermo Scientific, Waltham, MA).
Treatments—HDFs plated in 6-well plates were serum-starved overnight and treated 24h 
with 150μg/ml CM, growth factors (b-FGF, IL-8, PDGF-β, TGF-β and VEGF) or serum-free 
DMEM (control). Small molecule inhibitors (Supplementary Table 1) were applied 2 h 
before treatments.
CAFs isolation—Patient tumor samples were de-identified with 6-digit numbers. The 
protocol was approved by Northwestern University Institutional Review Board, and all 
patients provided informed consent. Fragments of tumor samples or patient-derived 
xenografts were cut into 1–2 mm pieces, and plated in GlutaMax DMEM or RPMI1640 with 
10% of FBS. After 2–16 weeks the cells were harvested with 0.25% Trypsin/EDTA (Life 
Technologies) and cryopreserved at passage 3.
Immunoblotting—Cells were lysed with M-PER buffer with protease/phosphatase 
inhibitors (Thermo Scientific, Waltham, MA), lysates cleared by centrifugation (8000g, 10 
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min, 4°C) and total protein measured. The lysares were resolved by SDS-PAGE (4–20% 
Tris-HCl polyacrylamide gels, Biorad, Hercules, CA) and transferred to PVDF membranes 
(GE Healthcare Life Sciences, Pittsburg, PA). The membranes were rinsed in Tris-buffered 
saline with 0.1% Tween 20 (TBS-T) and blocked 30 min in TBS-T with 5% non-fat milk. 
After incubation with 1° antibodies (Supplementary Table 2), the membranes were washed 
with TBS-T and incubated with secondary antibodies (Supplementary Table 3; 1 h, 5% non-
fat milk, TBS-T). Blots were developed with Enhanced Chemoluminescence kit (Thermo 
Scientific, Waltham, MA) and quantified by densitometry (ImageJ32 software, National 
Institutes of Health, Bethesda, MD). All values were corrected for the integrated optical 
density (iOD) and normalized to loading controls.
Image acquisition—Photomicrographs were taken with Nikon Diaphot 2000 microscope 
with bright-light and fluorescent digital cameras, Nikon Elements and Spot 5 software. 
Images were analyzed using Elements or ImageJ32 software. Western Blots were digitalized 
using Epson Scan software and plot profiles generated. The values for each band were 
calculated as (area under the curve) × iOD. Macroscopicl images were taken with Nikon 
CoolPix camera and quantified using Object Count function (ImageJ32).
Gene array analysis—Dermal fibroblasts were transduced with Sh-PEDF or Sh-Scr. 
Replicates of 3 were used for statistical evaluation. mRNA was extracted with Qiagen 
RNeasy kit (Qiagen, Valencia, CA) and analyzed at the University of Illinois at Chicago 
Genomic Core (Chicago, IL). Statistical significance was calculated by Student's t-test and P 
<0.05 considered significant. The expression differences > 1.5 were further validated by 
qRT-PCR.
RNA amplification—Total mRNA was reverse-transcribed using iScript cDNA kit (Bio-
Rad, Hercules, CA) and amplified with SsoAdvance SYBR Green Supermix, (Bio-Rad, 
Hercules, CA) in Bio-Rad CSF96 Real-Time Detection System. Human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), Tubulin or L19 were used as reference.
Statistical Analysis—All experiments were performed > 3 times and the samples tested 
in triplicates. Statistical significance was assessed by One-Way Anova with Bonferroni 
Multiple Comparison posttest for normally distributed datasets (established by Kolmogorov-
Smirnov test, GraphPad Prizm). For smaller/ non-normal datasets, non-parametric Kruskal-
Wallis or Mann-Whitney tests were applied and P < 0.05 set as significant.
Results
PEDF-null fibroblasts enhanced tumor growth
Fibroblasts are the second richest source of PEDF in skin (18) and PEDF from dermal 
fibroblasts could compensate for its lack in aggressive melanoma cells. To investigate this 
possibility, we generated PEDF-null human dermal fibroblasts (HDFs) using lentivirally 
expressed shRNA (sh-PEDF). Scrambled sequence was used as control (Sh-Scr). Western 
blot and qRT-PCR showed ~ 85% and ~ 60% reduction in PEDF protein and mRNA, 
respectively (Fig 1A, Supplementary Fig. 2). Sh-PEDF or Sh-Scr fibroblasts mixed 4:1 with 
C8161-HA melanoma cells, which express no detectable PEDF (18) were injected into the 
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flanks of nude mice (Fig 1B). C8161-HA cells alone served as control. After 14 days tumor 
growth was significantly enhanced by Sh-PEDF but not Sh-Scr fibroblasts as was evidenced 
by tumor weights and volumes (Fig 1C, Supplementary Fig. 3A). Accelerated growth in Sh-
PEDF was accompanied by increased proliferation (Ki67 staining, Fig 2D). The observed 
increase in proliferation occurred mainly in the tumor cells as was evidenced by minimal 
Ki67-positivity in GFP-expressing fibroblasts (Supplementary Fig. 4C).
Forced PEDF expression in cancer cells attenuates tumor growth by simultaneously inducing 
apoptosis and blocking angiogenesis; however, the contribution of fibroblast-derived PEDF 
has not been explored. We observed significantly higher apoptosis in the presence of Sh-Scr 
fibroblasts compared to the control and Sh-PEDF groups (Fig 2E). In contrast, the difference 
in the microvascular density (MVD) was not significant and the tumors containing Sh-Scr or 
Sh-PEDF fibroblasts presented with significantly higher MVD (Fig 1F).
To exclude potential fibroblasts' proliferation and apoptosis from analyses, C8161HA cells 
were injected in the right flanks of mice and the tumors allowed to establish 14 days, at 
which point mice were randomized into groups and injected in the dorsal midline with Sh-
Scr or Sh-PEDF fibroblasts or saline (Fig. 2A). In this setting, Sh-Scr fibroblasts 
significantly reduced tumor growth (Fig 2B, Supplementary Fig. 3C). The proliferative 
index (Ki67) remained higher in Sh-PEDF compared to Sh-Scr and control groups (Fig. 2C) 
and Sh-Scr tumors displayed increased apoptosis (Fig. 2D). There was no significant 
recruitment of GFP-tagged fibroblasts to the tumors (Supplementary Fig. 3D). Importantly, 
in contrast to the admixing experiment, Sh-Scr fibroblasts caused a significant reduction in 
MVD compared to Sh-PEDF and control groups (Fig. 2E).
This indicates that fibroblast-derived PEDF attenuates tumor growth and angiogenesis and 
suggest that anti-cancer effects of Sh-Scr fibroblasts are reduced when they are in close 
contact with tumor cells.
The lack of host PEDF increased metastasis
Ectopic PEDF reduces metastatic potential of melanoma cells by concomitant disruption of 
the amoeboid migration and MT1-MMP proteolysis (28). A recent study showed increased 
uveal melanoma metastasis in mice with global PEDF knockdown (29) but did not uncover 
the underlying mechanism. In agreement, subcutaneously injected of B16F10 melanoma 
cells formed larger metastasis with higher incidence in SERPINF1 KO mice compared to the 
wild-type controls (Fig. 3A, supplementary Table 3). Similarly, in SERPINF1 KO mice tail-
vein inoculation of B16F10 cells yielded more surface lung colonies, with increased the 
number and size of parenchymal micrometastases (Fig. 3B, C). This difference was not due 
increased extravasation, since the number of single-cell colonies formed by B16F10 cells 
24h post inoculation were similar in SERPINF1 KO and control mice (Fig. 3D).
Therefore, the invasive capacity of melanoma cells was unaffected by PEDF in the host 
tissue, and the observed differences were likely caused by decreased overall survival, due to 
reduced proliferation and elevated apoptosis.
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Tumor cells suppress PEDF production in the fibroblasts
PEDF-positive fibroblasts attenuated tumor growth and angiogenesis if injected 
independently of C8161-HA melanoma cells but lost their tumor suppressive properties 
when co-injected with cancer cells. We reasoned that fibroblasts in admixed tumors undergo 
partial CAF conversion, possibly due to PEDF decrease, and examined factors that could 
reduce PEDF expression.
In a growing tumor CAFs are exposed to hypoxic stress, which attenuates PEDF expression 
in melanoma cells (30). Similarly, exposure to hypoxia significantly reduced PEDF in the 
HDFs as was determined by Western blot (Fig. 4A).
In addition, tumor cells secrete growth factors and cytokines, which affect non-neoplastic 
cells in the TME (1). To investigate whether these factors attenuate PEDF levels in CAFs, 
HDFs were treated with CM from A375 and C8161-HA melanoma cells. Both CM 
considerably decreased PEDF in fibroblast lysates (Fig. 4B–C). This decrease was reversed 
by pan-RTK inhibitor Sorafenib (Selleckchem, Houston, TX, Fig. 4D–E), which has limited 
selectivity for VEGF and PDGF receptors. We then tested a series of growth factors 
expressed by aggressive melanoma, VEGF, bFGF, PDGF-BB, TGF-β and IL-8. Of these, 
PDGF-BB and TGF-β (used at concentrations in the range typically produced by melanoma 
cells (31)) caused a dose-dependent reduction of PEDF levels in fibroblasts (Fig. 4F); 
however, combined use of PDGF-BB and TGF-β had no additive effect (Fig. 4G). Q-PCR 
and ELISA confirmed significantly higher expression of PDGF-BB and TGF-β in A375 and 
C8161-HA cells (Fig. 4H and data not shown). Our findings indicate that melanoma cells 
attenuate PEDF expression by CAFs, which can be reduced by hypoxia and by tumor-
derived PDGF-BB and TGF-β. Interestingly, recombinant PDGF-BB dramatically reduced 
PEDF mRNA in cultured HDFs (Supplementary Fig. 5).
TGF-β enhances PEDF suppression by paracrine and autocrine PDGF-BB via JNK1/2, p38, 
PI3K and Erk1/2
PDGF-BB and TGF-β were sufficient to attenuate PEDF expression in CAFs. To establish 
whether these factor(s) are also necessary, we treated HDFs with A375 or C8161-HA CM in 
the presence of the inhibitors of PDGF-BB (Crenolanib) and TGF-β (LY364947). PDGF-BB 
inhibitor consistently reversed PEDF down-regulation by melanoma CM (Fig. 5A, B). In 
contrast, TGF-β inhibitor was ineffective at restoring PEDF expression but slightly 
augmented the effect of Crenolanib (Fig. 5A, B). We hypothesized that PDGF-BB, whose 
levels in melanoma cells exceed normal by 400–500 fold, directly inhibits PEDF expression, 
while the TGF-β effect is indirect. In agreement, PDGF-BB knockdown alleviated PEDF 
suppression by C8161-HA CM; this reversal was more pronounced in HDFs with TGFRB1 
knockdown (Supplementary Fig. 6).
TGF-β is known to up-regulate PDGF receptors in hepatic cells (32). Similarly, PDGFR-β 
was significantly higher in primary fibroblasts treated with TGF-β (Fig. 5C). Intriguingly, 
PEDF suppression by TGF-β was reversed by Crenolanib (Fig. 5D). We reasoned that in 
melanoma, PDGF-BB is the main factor, which blocks PEDF expression in GCAFs and that 
TGF-β exacerbates this effect by up-regulating PDGFR. The PDGFR-α and β mRNAs were 
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unaltered by TGF-β (Supplementary Fig. 7). In contrast, TGF-β increased PDGF-BB mRNA 
in HDFs (Supplementary Fig. 8), suggesting an autocrtine feedback loop that further 
attenuates PEDF expression.
Seeking protein kinases involved in PEDF regulation, we found that JNK1/2 and p38 
inhibitors but not ERK1/2 inhibitor reversed PEDF down-regulation by PDGF-BB, TGF-β or 
C8161-HA CM (Fig. 5E–G). Further, the PDGFR upregulation by TGF-β was abolished by 
the PI3K inhibitor Wortmannin, diminished by 50–30% with JNK1/2, p38 and Erk1/2 
inhibitors (Fig. 5H, Supplementary Fig. 9).
Our results define a crosstalk between melanoma cells and skin fibroblasts in which 
fibroblast-derived PEDF inhibits melanoma growth and angiogenesis. Aggressive 
melanomas secrete PDGF-BB, which reduces PEDF expression in adjacent fibroblasts, a 
process that requires JNK1/2 and p38, and TGF-β, which further sensitizes fibroblasts to 
PDGF-BB by upregulating PDGFR-β, mainly via p38 and PI3K and increased PDGF-BB 
expression by fibroblasts (Fig. 5I).
PEDF repeals CAF Conversion
Our findings suggest that PEDF loss enables CAF conversion. In TGF-β-activated HDFs. 
PEDF significantly dampened the increase of CAF marker α-SMA (6) (Fig. 6A) and 
inhibited TGF-β signaling as was evidenced by ~ 3-fold decrease of SMAD2/3 
phosphorylation (Fig. 6B). PEDF also non-canonical TGF-β signaling ias was evidenced by 
decreased Erk1/2 activation (Supplementary Fig. 10). Interestingly, PEDF treatment strongly 
elevated cytoplasmic PEDF levels in the activated fibroblasts (2.5 - 6 fold, Fig. 6C and F), 
suggesting a positive feedback loop. In agreement, PicoSirius staining of the tumors from 
the in vivo experiments showed increased collagen deposition in C8161 tumors when Sh-
PEDF but not Sh-Scr fibroblasts were injected in a remote site (Fig. 6D). Consistent 
attenuated PEDF expression on contact with melanoma cells, both Sh-PEDF and Sh-Scr 
fibroblasts augmented collagen deposition when comixed with melanoma cells (Fig. 6E). 
Moreover, expression profiling of Sh-PEDF and Sh-Scr fibroblasts showed significant 
upregulation of Hyaluronan Synthase 2 (HAS2), IL-8, Serpin B2, Stanninocalcin (STC)-1 
and NADPH Oxidase (NOX)4 in response to PEDF knockdown, (Supplementary Fig. 11).
Fibroblasts isolated from the patient tumors of varying origin all showed strikingly low 
levels of PEDF (Fig. 6F). As in TGF-β treated fibroblasts, exogenous PEDF significantly 
increased its own expression. While it had no significant effect on α-SMA, there was a 
significant decrease in mesenchymal marker vimentin, which could be indicative of 
normalization process due to disrupted TGF-β signaling.
Together, our results support the notion that PEDF is an endogenous factor that maintains 
tumor suppressive qualities of the fibroblasts (see discussion). This is important, because the 
microenvironment factors that maintain fibroblasts in their normal, tumor-suppressive state 
are not known and PEDF may be the first of such factors described.
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Discussion
To date, most studies focused on the tumor-promoting role of CAFs, however, some clearly 
demonstrate the heterogeneity of CAFs and their potent tumor-suppressive effects (reviewed 
in (33, 34)). Fibroblast depletion of in a mouse model of pancreatic carcinoma is causes 
accelerated tumor progression, immunosuppression, and drug resistance (35). Another study 
shows potent tumor-suppressive effects of CAFs from breast cancer specimens expressing 
Slit2 (36). Similarly, PTEN expression by stromal fibroblasts conveys tumor suppressive 
effects, by stimulating miR-320, an inhibitor of Ets2 dependent transcription (37–39). A 
more recent study shows tumor suppressive properties of podoplanin-expressing fibroblasts 
in lung cancer (40). In light of these observations, a new model has been proposed, where 
CAFs, like tumor-associated macrophages, can be polarized towards F1 (tumor-suppressive) 
and F2 (tumor-promoting) states (33). While the factors driving F1-F2 conversion are well 
known (TGF-β, PDGF-BB, SDF-1), little is known about extracellular molecules that can 
cause or maintain F1 state and PEDF may be the first such protein identified.
The consequences and underlying mechanisms of PEDF loss by the tumor cells have been 
extensively studied; however, PEDF role and regulation in the tumor microenvironment is 
poorly understood. We have focused on the role of fibroblast-derived PEDF. Recent studies 
in PEDF null mice established its role as an anti-fibrotic factor in the liver and pancreas (41, 
42) suggesting that PEDF down-regulation in fibroblasts, where it is normally high, may be 
essential for their conversion to tumor-promoting, F2 CAFs.
Using in vivo models where PEDF-positive or PEDF-null fibroblasts generated by shRNA 
knockdown are combined with melanoma cells, we were able to corroborate and in part 
explain earlier findings where host-derived PEDF interferes with tumor dissemination (29). 
In mice with pre-established subcutaneous melanoma, we showed that fibroblasts lacking 
PEDF accelerated tumor growth by decreasing apoptosis, enhancing proliferation and 
promoting angiogenesis. In contrast, PEDF-positive, normal fibroblasts reduced tumor 
angiogenesis as was evidenced by a significant decrease in MVD compared to control 
tumors in the absence of exogenous fibroblasts. Importantly, the effect of exogenously added 
PEDF-positive fibroblasts was significantly dampened by contact with the tumor cells. Co-
injection with C8161-HA melanoma cells attenuated HDF's ability to halt tumor growth and 
angiogenesis, in contrast with their effect when inoculated remotely. This could be explained 
if close proximity to melanoma cells attenuated PEDF expression in fibroblasts.
Indeed, we discovered that even 24-h exposure of primary dermal fibroblasts to the media 
conditioned the PEDF null melanoma cells significantly reduced PEDF expression. Using 
pharmacologic inhibitors and direct screening, we identified PDGF-BB and TGF-β among 
factors secreted by the melanoma cells, as sufficient to attenuate PEDF expression. Both 
PDGF-BB and TGF-β play prominent roles in the formation of reactive stroma in solid 
tumors. PDGF-BB is thought to be critical for fibroblast recruitment and proliferation, while 
TGF-β is considered one of the main factors that cause F1 - F2 conversion (normal 
fibroblasts to CAFs), with up-regulated expression of ECM components, pro-fibrotic and 
pro-invasive factors (43). We found that JNK and p38, but not Erk1/2 were required for this 
PEDF reduction. Intriguingly, using specific inhibitors of PDGFR and TGF-β signaling, we 
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found that only PDGF-BB directly inhibited PEDF protein expression, while TGF-β1 
modulated PEDF expression indirectly, by up-regulating PDGF receptor. This was suggested 
by the fact that PDGF inhibitor, Crenolanib, reversed PEDF reduction caused by TGF-β. Our 
findings are consistent with prior results, were TGF-β1 was found to enhance PDGFR-β 
expression in hepatic stellate cells (32). Further analysis showed that PDGFR-β induction by 
TGF-β1 required PI3K, JNK1/2, p38 and to a lesser degree Erk1/2. Moreover, we found that 
TGF-β also up-regulated PDGF-BB ligand. Together our findings suggest that PDGF-BB is 
a direct regulator of PEDF expression, whereas TGF-β controls PEDF levels by 
enhancement of PDGF-BB expression and signaling (summarized in Fig. 5I).
Our in vivo results combined with in vitro findings led us to conclude that PEDF may 
control the activation state of the fibroblasts whereby high PEDF levels are consistent with 
quiescence and normal (F1) polarization state, while low PEDF levels signify activation and 
conversion to CAFs and F2 polarization. This hypothesis is in agreement with the previous 
findings that PEDF is expressed at high levels in non-stimulated early-passage fibroblasts 
and is down-regulated when they become proliferative (44) or senescencent (45). Loss of 
fibroblastic PEDF appears permissive to F2 polarization (CAF conversion) since PEDF 
inhibits TGF-β responses in primary fibroblasts, including SMAD signaling, Erk1/2 
signaling and the F2 marker, α-SMA. Moreover, PEDF knockdown fibroblasts caused 
overall changes in fibroblast expression profile, which favor tumor progression. The up-
regulated genes included HAS2, which is responsible for deposition of hyaluronan (HA). 
HA is a CD44 ligand and predictor of poor prognosis and metastasis in multiple cancers 
types, due in part to CD44-dependent recruitment of cancer stem cells (46). IL-8 is a known 
pro-inflammatory, pro-angiogenic chemokine whose with well established role in cancer 
including melanoma (47). Stanniocalcin-1 expression specifically by CAFs also is 
associated with poor prognosis and metastasis in cancers including melanoma (48). Most 
interesting, SERPINB2 (Plasminogen Activator Inhibitor 2) functions as a tumor suppressor, 
when expressed by cancer cells (49) but becomes a clear-cut oncogene if expressed by 
fibroblasts. In breast cancer models, it contributes to the formation of autophagic stroma, 
which fuels mitochondrial metabolism in cancer cells and promotes metastasis (50) or 
enables cancer cell survival and vascular cooption in the brain (51).
Our results point to PEDF as a critical factor that maintains F1 polarization of fibroblasts 
and limits their contribution to tumor progression. Tumors expressing high PDGF-BB levels 
overcome the negative pressure exerted by F1 fibroblasts by decreasing their PEDF 
production. This effect is further augmented by TGF-β, which up-regulates PDGFR-β. Our 
findings were corroborated by the fact that PEDF expression was extremely low in CAFs 
cultured from three types of human tumors and that exogenous PEDF attenuated some of the 
CAF F2 markers, and restored its own expression. Based on our observations, it is 
conceivable that pharmacologic inhibitors of PDGF-B and TGF-β can restore PEDF 
expression in fibroblasts in vivo, and could restrain or reverse fibroblasts activation and 
restore PEDF in the tumor milieu. In turn, fibroblasts derived-PEDF may elicit paracrine 
effects in the TME including inhibition of endothelial and tumor cell proliferation, induction 
of apoptosis and anti-tumor immune response (M1 macrophage polarization). Our findings 
also support the use of PEDF small peptide mimetics as therapeutic approach to enforce the 
normal state of tumor stroma and prevent tumor fibrosis and metastasis.
Nwani et al. Page 11
Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
This study was funded by the following grants: T32 Carcinogenesis Training grant CA60013828 (NN), NCI R01 
CA172669 (OV) and SAF2014-53819-R grant from Ministerio de Ciencia y Competitividad of Spain (BJ). AM, 
AU and OD were supported by the Baskes Family Research Fund. Primary fibroblast cultures and lentiviral stocks 
were generated at NU Skin Disease Research Core). CAFs were isolated at NU Center for Developmental 
therapeutics. We also thank Dr. Stanley Wiegand (Regeneron) for the gift of SERPINF1 KO mice.
CITATIONS
1. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor 
microenvironment. Cancer cell. 2012; 21(3):309–22. [PubMed: 22439926] 
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature reviews Cancer. 2006; 6(5):392–401. [PubMed: 
16572188] 
3. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Current 
opinion in genetics & development. 2001; 11(1):54–9. [PubMed: 11163151] 
4. Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. 
Seminars in cancer biology. 2014; 25:61–8. [PubMed: 24560651] 
5. Kim SH, Hwang SM, Lee JM, Kang JH, Chung IY, Chung BG. Epithelial-to-mesenchymal 
transition of human lung alveolar epithelial cells in a microfluidic gradient device. Electrophoresis. 
2013; 34(3):441–7. [PubMed: 23161566] 
6. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer 
progression. British journal of cancer. 2008; 99(9):1375–9. [PubMed: 18797460] 
7. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Molecular cancer 
research : MCR. 2014; 12(3):297–312. [PubMed: 24452359] 
8. Santi A, Caselli A, Paoli P, Corti D, Camici G, Pieraccini G, et al. The effects of CA IX catalysis 
products within tumor microenvironment. Cell communication and signaling : CCS. 2013; 11:81. 
[PubMed: 24168032] 
9. Hoffman RM. Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised 
niche. Breast cancer research : BCR. 2013; 15(3):310. [PubMed: 23806092] 
10. Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. 
Seminars in cancer biology. 2014; 25:15–22. [PubMed: 24412104] 
11. Donovan J, Abraham D, Norman J. Platelet-derived growth factor signaling in mesenchymal cells. 
Front Biosci (Landmark Ed). 2013; 18:106–19. [PubMed: 23276912] 
12. Braicu C, Tudoran O, Balacescu L, Catana C, Neagoe E, Berindan-Neagoe I, et al. The 
significance of PDGF expression in serum of colorectal carcinoma patients--correlation with 
Duke's classification. Can PDGF become a potential biomarker? Chirurgia (Bucur). 2013; 108(6):
849–54. [PubMed: 24331325] 
13. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, et al. Prognostic significance 
of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. The 
American journal of pathology. 2009; 175(1):334–41. [PubMed: 19498003] 
14. Lisanti MP, Martinez-Outschoorn UE, Sotgia F. Oncogenes induce the cancer-associated fibroblast 
phenotype: metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug 
discovery. Cell Cycle. 2013; 12(17):2723–32. [PubMed: 23860382] 
15. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an 
easy way out. Cancer letters. 2013; 341(1):80–96. [PubMed: 23376253] 
16. Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, et al. Paracrine effect of NRG1 and 
HGF drives resistance to MEK inhibitors in metastatic uveal melanoma. Cancer research. 2015
Nwani et al. Page 12
Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
17. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, et al. Intravital Imaging 
Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin 
beta1/FAK Signaling. Cancer cell. 2015; 27(4):574–88. [PubMed: 25873177] 
18. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, Aguilera O, et al. `Loss of pigment 
epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'. 
Oncogene. 2009; 28(47):4147–61. [PubMed: 19767774] 
19. Becerra SP, Notario V. The effects of PEDF on cancer biology: mechanisms of action and 
therapeutic potential. Nature reviews Cancer. 2013; 13(4):258–71. [PubMed: 23486238] 
20. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-
derived factor: a potent inhibitor of angiogenesis. Science. 1999; 285(5425):245–8. [PubMed: 
10398599] 
21. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas 
targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment 
epithelium-derived factor. Nature medicine. 2002; 8(4):349–57.
22. Biyashev D, Veliceasa D, Kwiatek A, Sutanto MM, Cohen RN, Volpert OV. Natural angiogenesis 
inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor gamma 
(PPARgamma). The Journal of biological chemistry. 2010; 285(18):13517–24. [PubMed: 
20185831] 
23. Ho TC, Chen SL, Yang YC, Liao CL, Cheng HC, Tsao YP. PEDF induces p53-mediated apoptosis 
through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovascular 
research. 2007; 76(2):213–23. [PubMed: 17651710] 
24. Li L, Yao YC, Fang SH, Ma CQ, Cen Y, Xu ZM, et al. Pigment epithelial-derived factor (PEDF)-
triggered lung cancer cell apoptosis relies on p53 protein-driven Fas ligand (Fas-L) up-regulation 
and Fas protein cell surface translocation. The Journal of biological chemistry. 2014; 289(44):
30785–99. [PubMed: 25225287] 
25. Ho TC, Chen SL, Shih SC, Chang SJ, Yang SL, Hsieh JW, et al. Pigment epithelium-derived factor 
(PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). The Journal of biological chemistry. 2011; 286(41):
35943–54. [PubMed: 21846721] 
26. Nelius T, Samathanam C, Martinez-Marin D, Gaines N, Stevens J, Hickson J, et al. Positive 
correlation between PEDF expression levels and macrophage density in the human prostate. The 
Prostate. 2013; 73(5):549–61. [PubMed: 23038613] 
27. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikstrom P, Bergh A. Pigment epithelium-derived 
factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor 
microenvironment. Neoplasia. 2010; 12(4):336–45. [PubMed: 20360944] 
28. Ladhani O, Sanchez-Martinez C, Orgaz JL, Jimenez B, Volpert OV. Pigment epithelium-derived 
factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal 
proteolysis. Neoplasia. 2011; 13(7):633–42. [PubMed: 21750657] 
29. Lattier JM, Yang H, Crawford S, Grossniklaus HE. Host pigment epithelium-derived factor (PEDF) 
prevents progression of liver metastasis in a mouse model of uveal melanoma. Clinical & 
experimental metastasis. 2013; 30(8):969–76. [PubMed: 23793989] 
30. Fernandez-Barral A, Orgaz JL, Gomez V, del Peso L, Calzada MJ, Jimenez B. Hypoxia negatively 
regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, 
autophagy dependent mechanism. PloS one. 2012; 7(3):e32989. [PubMed: 22457728] 
31. Elias EG, Hasskamp JH, Sharma BK. Cytokines and growth factors expressed by human cutaneous 
melanoma. Cancers. 2010; 2(2):794–808. [PubMed: 24281094] 
32. Shah R, Reyes-Gordillo K, Arellanes-Robledo J, Lechuga CG, Hernandez-Nazara Z, Cotty A, et al. 
TGF-beta1 up-regulates the expression of PDGF-beta receptor mRNA and induces a delayed 
PI3K-, AKT-, and p70(S6K) -dependent proliferative response in activated hepatic stellate cells. 
Alcoholism, clinical and experimental research. 2013; 37(11):1838–48.
33. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor 
microenvironment. Frontiers in oncology. 2014; 4:62. [PubMed: 24734219] 
34. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth--bystanders turning into 
key players. Current opinion in genetics & development. 2009; 19(1):67–73. [PubMed: 19211240] 
Nwani et al. Page 13
Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of 
carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates 
pancreas cancer with reduced survival. Cancer cell. 2014; 25(6):719–34. [PubMed: 24856586] 
36. Chang PH, Hwang-Verslues WW, Chang YC, Chen CC, Hsiao M, Jeng YM, et al. Activation of 
Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via 
blocking PI3K/Akt/beta-catenin pathway. Cancer research. 2012; 72(18):4652–61. [PubMed: 
22826604] 
37. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, et al. 
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nature 
cell biology. 2012; 14(2):159–67. [PubMed: 22179046] 
38. Wallace JA, Li F, Leone G, Ostrowski MC. Pten in the breast tumor microenvironment: modeling 
tumor-stroma coevolution. Cancer research. 2011; 71(4):1203–7. [PubMed: 21303970] 
39. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, et al. Pten in stromal 
fibroblasts suppresses mammary epithelial tumours. Nature. 2009; 461(7267):1084–91. [PubMed: 
19847259] 
40. Takahashi A, Ishii G, Neri S, Yoshida T, Hashimoto H, Suzuki S, et al. Podoplanin-expressing 
cancer-associated fibroblasts inhibit small cell lung cancer growth. Oncotarget. 2015; 6(11):9531–
41. [PubMed: 25909164] 
41. Schmitz JC, Protiva P, Gattu AK, Utsumi T, Iwakiri Y, Neto AG, et al. Pigment epithelium-derived 
factor regulates early pancreatic fibrotic responses and suppresses the profibrotic cytokine 
thrombospondin-1. The American journal of pathology. 2011; 179(6):2990–9. [PubMed: 
21964188] 
42. Tsai TH, Shih SC, Ho TC, Ma HI, Liu MY, Chen SL, et al. Pigment Epithelium-Derived Factor 34-
mer Peptide Prevents Liver Fibrosis and Hepatic Stellate Cell Activation through Down-
Regulation of the PDGF Receptor. PloS one. 2014; 9(4):e95443. [PubMed: 24763086] 
43. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. American journal of 
cancer research. 2011; 1(4):482–97. [PubMed: 21984967] 
44. Coljee VW, Rotenberg MO, Tresini M, Francis MK, Cristofalo VJ, Sell C. Regulation of EPC-1/
PEDF in normal human fibroblasts is posttranscriptional. Journal of cellular biochemistry. 2000; 
79(3):442–52. [PubMed: 10972981] 
45. Pignolo RJ, Cristofalo VJ, Rotenberg MO. Senescent WI-38 cells fail to express EPC-1, a gene 
induced in young cells upon entry into the G0 state. The Journal of biological chemistry. 1993; 
268(12):8949–57. [PubMed: 8473338] 
46. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005; 106(6):1901–
10. [PubMed: 15890683] 
47. Singh S, Singh AP, Sharma B, Owen LB, Singh RK. CXCL8 and its cognate receptors in 
melanoma progression and metastasis. Future Oncol. 2010; 6(1):111–6. [PubMed: 20021212] 
48. Pena C, Cespedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, et al. STC1 
expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer research. 
2013; 73(4):1287–97. [PubMed: 23243022] 
49. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiology of 
haemostasis and thrombosis. 2008; 36(3–4):184–94. [PubMed: 19176991] 
50. Castello-Cros R, Bonuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, et al. Matrix 
remodeling stimulates stromal autophagy, “fueling” cancer cell mitochondrial metabolism and 
metastasis. Cell Cycle. 2011; 10(12):2021–34. [PubMed: 21646868] 
51. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell 
survival and vascular co-option in brain metastasis. Cell. 2014; 156(5):1002–16. [PubMed: 
24581498] 
Nwani et al. Page 14
Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. PEDF Loss in Resident Fibroblasts Enhanced Tumor Growth
(A) PEDF-null fibroblasts were generated by knockdown with lentiviral shRNA specific to 
PEDF (sh-PEDF). Scrambled shRNA (sh-Scr) was used as a negative control. The 
knockdown was verified by Western blot. WT, wild type, uninfected fibroblasts. (B) 
Experimental design. Nude mice were inoculated s.c. with C8161-HA melanoma cells (106) 
alone (control) or admixed with 1:4 with sh-Src or sh-PEDF fibroblasts; two weeks post-
injection the tumors were harvested and the following parameters assessed: (C) tumor mass; 
(D) Proliferation (Ki67 immunofluorescence); (E) Apoptosis (in situ TUNEL); (F) MVD 
(CD31 immunofluorescence). Digital images were analyzed using “Object Count” function 
of the Elements software. The SEM and P values were calculated using Graph Pad Prism 
software.
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Figure 2. PEDF-expressing fibroblasts injected at a distant site inhibited tumor growth and 
angiogenesis
(A) C8161-HA cells (106) were injected subcutaneously in the right flanks of nude mice. 
Fourteen days post injection palpable tumors formed and the mice were injected with 106 
HDFs (PEDF status indicated) or 100 μl saline (control) at the dorsal midline. Two weeks 
after HDF injection tumors were harvested and evaluated. (B) Tumor mass; (C) Proliferation 
(Ki67 immunofluorescence); (D) Apoptosis (TUNEL); (E) Microvascular density (CD31 
immunofluorescence, red). Digital images were taken at 20× magnification and no less than 
5 random field per section evaluated. The SEM values are shown. P values were determined 
using Graph Pad Prism software.
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Figure 3. Lack of PEDF in the tumor microenvironment promotes metastasis
(A) B16F10 melanoma cells (105) were injected into the flanks of wild type (WT) and 
PEDF-null (SERPINF1 KO) mice (n=8) to evaluate spontaneous metastasis. Alternatively, 
105 cells were injected into the tail vein of WT and SERPINF1 KO mice (n=5) to assess 
lung colonization. (B) Three weeks after primary tumor implantation, autopsy was 
performed and spontaneous abdominal and pleural metastasis counted and measured. (C) 
Two weeks after tail vein injection, mice were sacrificed, lungs photographed (representative 
images are shown) and surface colonies counted using ImageJ software. (D) Lungs from 
were also formalin-fixed and paraffin-embedded, 5 μm thick sections stained with 
Hematoxylin/ Eosine and micrometastases number and area per animal determined using 
ImageJ software. (E) Extravasation of CDFA-SE labeled B16F10 cells from the lung 
vasculature was assessed in WT and SERPINF1 KO mice 2 h and 24 h after tail vein 
inoculation. Shown are the representative fluorescence images of the lung surface at 2 h and 
24 h, obtained with Nikon AZ-100 microscope (5× objective) and quantitative analysis at a 
24 h time point (Nikon Elements software).
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Figure 4. Tumor-associated Factors Down-regulate PEDF Expression in Fibroblasts
PEDF levels were measured in primary HDFs, exposed to hypoxic (H) or normoxic (N) 
conditions or treated with CM from melanoma cells. (A) HDFs were serum starved and 
exposed to hypoxa for 24 h; PEDF levels in cell lysates and in CM were assessed by 
Western blot. (B, C) HDFs were treated 24 h with CM from A375 or C8161 cells (150 μg/ml 
protein final concentration). (D, E) HDFs were treated 24 h with A375 or C8161-HA CM in 
the presence of 10 μM Sorafenib. (F) HDFs were exposed for 24 h to increasing 
concentrations of growth factors and PEDF levels evaluated by Western blot. (G) HDFs 
were treated with PDGF-BB and TGF-β alone and in combination and PEDF levels assessed 
by Western blot. (H) QRT-PCR measurement of mRNA levels of PDGF-β and TGF-β in 
A375 and C8161-HA melanoma cell lines and primary melanocytes (normalized to 
GAPDH).
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Figure 5. TGF-β and PDGF-BB down-regulation of PEDF expression in Fibroblasts via 
Paracrine and Autocrine molecular events
(A, B) Normal HDFs were incubated 24 h with CM from A375 and C8161 cells with and 
without PDGF-BB (Crenolanib) or TGF-β (LY364947) inhibitors; PEDF in cell lysates was 
measured by western blot. (C) PEDF expression in HDFs treated with PDGF-β (100 ng/ml) 
or TGF-β (10 ng/ml) with or without their respective inhibitors Crenolanib or Ly364947. (D) 
To assess the effects of autocrine PDGF-BB, fibroblasts were Crenolanib; TGF-β was added 
were indicated. (E & F) HDFs were treated 24h with PDGF-BB or TGF-β in the presence or 
in the absence of inhibitors of ERK ½ (U0126), JNK1/2 (SP600125) or p38 (SB203580). 
For concentrations see Supplementary Table 1. PEDF in cell lysates was detected by western 
blot. (G) PEDF expression in primary HDFs treated with C8161 CM (150 μg/ml) in the 
presence Erk1/2, JNK1/2 and p38 inhibitors as above. (H) PDGFR expression in primary 
HDFs treated with TGF-β in the presence of inhibitors of Erk1/2 JNK1/2, p38 and PI3K 
(Wortmannin), respectively. (I) Schematic presentation of the interplay between melanoma 
cells and fibroblasts, including secreted factors and signaling intermediates.
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Figure 6. PEDF attenuates fibroblast conversion to CAFs
(A) Primary HDFs were treated 72 h with TGF-β with and without exogenous PEDF (20 
nM). Myofibroblast marker α-SMA was assessed in cell lysates by Western blot. 
Densitometry results normalized to GAPDH are shown below each panel. (B) HDFs were 
treated for 24 h as in (A). Phospho-SMAD2/3, and total SMAD were assessed in cell lysates 
and the results normalized to the total SMAD2/3 (representative experiment of 5 is shown). 
(C) Cells were treated as above and PEDF levels assessed (normalized to GAPDH). (D, E) 
C8161-HA tumors from experiments in Fig. 1 and 2 were stained with PicoSirius Red to 
assess matrix deposition and quantified with ImageJ software. (F) CAFs from patient tumors 
(glioblastoma, GB2M7, breast, BC1M2, and prostate carcinoma, PCM1172) were evaluated 
for PEDF expression and treated with 10 and 20 nM exogenous PEDF. Note decreased 
vimentin expression in PEDF-treated fibroblasts and low pre-treatment PEDF levels in the 
cytoplasm, which increase after PEDF exposure.
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